COMPANY INFO
Miist Therapeutics is a private pharmaceutical company founded in 2019 by Dalton Signor. It is headquartered in Alameda, CA, with about 5 employees. The company develops inhaled therapies designed to provide rapid symptom relief, particularly for smoking cessation and migraine relief, using clinically validated aerosol physics technology. Its website is https://www.miisttherapeutics.com/. (PitchBook, Tracxn)
MiistMed is an innovative pharmaceutical company founded in 2022 by Dalton Signor and headquartered in Alameda, California. Focused on the development of inhaled therapies, MiistMed is advancing rapid symptom relief treatments, including solutions for smoking cessation and migraine relief, utilizing advanced aerosol physics technology. Leveraging a highly specialized team based out of its corporate headquarters in Alameda, MiistMed aims to pioneer new treatment modalities with clinically validated efficacy.
MiistMed funding history showcases a robust strategy, raising a total of $13.6 million across multiple rounds. The company has completed two Series A rounds in rapid succession, reflecting strong investor confidence and momentum toward both clinical development and product launch. Key funding milestones include a substantial Seed Round in 2022 and the backing of notable venture capital investors. MiistMed’s funding approach emphasizes early-stage innovation, validation, and the establishment of a firm clinical foundation for its unique inhalable therapies.
This Series A round was aimed at advancing inhaled therapies for rapid symptom relief, specifically driving forward treatments for migraine and smoking cessation into advanced clinical stages.
Proceeds from this Series A round were dedicated to robust clinical trials and accelerating the product development pipeline for MiistMed's inhaled therapies.
The Seed Round provided funding for MiistMed’s initial launch, supporting pre-clinical trials, early development of the proprietary inhaled therapy platform, and team expansion.
Early accelerator funding helped fuel pre-clinical research and development, solidifying the technical foundation necessary for subsequent venture capital investment.
Refactor Capital is a leading venture capital firm known for its focus on disruptive biotech startups. As a key investor in MiistMed funding rounds, they played a major role in fueling Series A growth and strategic initiatives.
Specializing in backing early-stage technology and science-driven startups, 1517 Fund has contributed across MiistMed's funding history, demonstrating ongoing confidence in the company’s products and team.
Freeflow Ventures is an early-stage venture capital investor supporting innovative healthcare solutions. Their involvement in multiple MiistMed investment rounds reflects their commitment to funding breakthrough therapeutic approaches.
Entrepreneur First is an accelerator and venture capital network that builds and invests in high-potential founders. Their participation in MiistMed’s funding indicates belief in the company's leadership and differentiated scientific model.
California Innovation Fund supports startups combing scientific innovation with commercial impact. As a MiistMed investor, they have played a role in both seed and growth rounds.
ZeroTo510 is an accelerator program specializing in medical device and healthcare startups. They provided early accelerator and seed funding, instrumental in MiistMed’s foundational phase.
Contributing during the Seed Round, Knollwood Investment Advisory helped MiistMed secure critical early capital to launch development and trial phases.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching MiistMed funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.